-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
紫金县|
莒南县|
壶关县|
西青区|
贺州市|
辽阳县|
合川市|
土默特右旗|
巴青县|
兰考县|
昌都县|
交城县|
灌阳县|
科技|
桂东县|
涿州市|
清新县|
渭源县|
长海县|
鄢陵县|
阿拉尔市|
北海市|
广南县|
漾濞|
淮南市|
萨嘎县|
和平区|
河津市|
庄河市|
绥芬河市|
贵州省|
长武县|
古浪县|
三都|
偏关县|
新乡市|
襄樊市|
宝鸡市|
和硕县|
宽甸|
澄城县|